HIV/AIDS Programme USER GUIDE DRUG REGULATORY STATUS DATABASE (DRS) Version 2
|
|
- Mabel Bertha Dorsey
- 6 years ago
- Views:
Transcription
1 HIV/AIDS Programme USER GUIDE DRUG REGULATORY STATUS DATABASE (DRS) Version 2 November 2012
2
3 HIV/AIDS Programme USER GUIDE DRUG REGULATORY STATUS DATABASE (DRS) Version 2 November 2012
4 WHO Library Cataloguing-in-Publication Data: User guide: Drug Regulatory Status Database (DRS) version 2. 1.Drug and narcotic control. 2.Essential drugs. 3.HIV infections drug therapy. 4.Anti-Retroviral agents supply and distribution 5.Handbooks. 6.Databases, Pharmaceutical. I.World Health Organization. ISBN (NLM classification: WC 503.2) World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site ( or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: ; fax: ; bookorders@who.int). Requests for permission to reproduce or translate WHO publications whether for sale or for noncommercial distribution should be addressed to WHO Press through the WHO web site ( about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Layout by Genève Design
5 CONTENTS 1. Introduction Objective Mandate Funding DRS Access Terminology DRS Data Data Source Data Entry and Verification Quality Assurance Procedures Caveats Product Categories Antiretroviral drugs (ARVs) TB medicines Artemisinin-based combination therapies (ACTs) Reports Types of reports Accessing reports Frequently Asked Questions How often is the DSR data updated? What is the added value of the DRS? Does the DRSD include pharmaceutical products used in the private sector market? Can the DRS be expanded to include all essential medicines? Why is the pharmaceutical product registration period not specified in the DRS? Communication/Visibility Quarterly report Feedback
6 1. INTRODUCTION 1.1 Objective The Drug Regulatory Status Database (DRS) was initially established in 2008 by the AIDS Medicines and Diagnostics Service (AMDS) of the World Health Organization (WHO) HIV Department, and updated in AMDS is a network of technical partners providing support and guidance to countries regarding their procurement and supply management of HIV commodities. The WHO HIV Department hosts the AMDS secretariat, and represents WHO in the partnership. The DRS is a database of the registration status of antiretroviral drugs in low, lower middle and upper middle income countries. 1 The DRS focuses only on ARVs which have been approved through the WHO prequalification programme or have been approved through a stringent regulatory process. The rationale behind its creation was to assist countries with procurement and supply chain management decisions, by providing actual drug registration status in countries, which would ultimately expedite in-country delivery of drugs. 1.2 Mandate Since its creation in 2008, the DRS has focused on monitoring the registration and marketability of ARVs in low/lower-middle/upper-middle income countries. In 2011, its scope was extended to cover tuberculosis (TB) medicines. However, the TB data will only be available in the public domain during the first quarter Funding To date, the project has been funded by WHO and the Bill and Melinda Gates Foundation. 1.4 DRS Access The DRS is available online at: and currently includes only ARV registration information. It is recommended that you read and familiarize yourself with this User Guide before you access the DRS. 1 The classification of countries is done using the World Bank Atlas classification method and is based on Gross National Income per capita. 2
7 2. TERMINOLOGY Brand Name: Proprietary name or trademark and identifies one particular drug from one seller. One drug can be sold under several brand names Country of manufacture: Country in which a pharmaceutical product has been produced by the manufacturer. Dosage form: The physical type and amount of a medication and includes capsules, tablets, injections, liquids, creams and suppositories. GFQA Standard: The Global Fund Quality Assurance standard (ARVs and TB medicines which have been approved through the WHO prequalification programme or have been approved through a stringent regulatory process) International Nonproprietary Names (INN): Identify pharmaceutical substances or active pharmaceutical ingredients. Each INN is a unique name that is globally recognized and is public property. A nonproprietary name is also known as a generic name Manufacturer: A company that produces, packages, repackages, labels and/or relabels pharmaceutical products. Manufacturing site: The site where the pharmaceutical product was manufactured. Pharmaceutical product: Any substance or combination of substances marketed or manufactured to be marketed for treating or preventing disease in human beings, or with a view to making a medical diagnosis in human beings, or to restoring, correcting or modifying physiological functions in human beings. Prequalification: WHO standardized quality assessment procedure to evaluate the acceptability, in principle, of pharmaceutical products for purchase by United Nations agencies. Quality standards: The benchmark to ensure that products and services are safe. Status: The registration status of a specific pharmaceutical product. Strength: The strength of the active ingredient contained in a pharmaceutical product. Stringent Regulatory Authority (SRA): An International Committee on Harmonisation (ICH) member country, an ICH observer or any country whose regulatory authority is associated with an ICH member through a legally binding mutual recognition agreement. Therapeutic category: Used to differentiate TB medicines from HIV drugs WHO Prequalification: Refers to the prequalification of medicines and means the process of ensuring that medicines for high burden diseases meet global standards of quality, safety and efficacy, in order to optimize the use of health resources and improve health outcomes. 2 2 Refer to 3
8 3. DRS DATA 3.1 Data Source The DRS indicates the in-country registration status of pharmaceutical products, based on information voluntarily provided to WHO by manufacturers. The data is provided to WHO for the sole purpose of inclusion in the DRS. The data is not available for dissemination to 3rd parties other than via the DRS mechanism. 3.2 Data Entry and Verification There is no standard format for data entry and this ensures that the provision of data and database entry is a straightforward procedure. Data is sent to WHO periodically by Manufacturers. Thereafter, the data is uploaded into the DRS and screened by WHO to ensure that there are no duplications. This includes randomized requests by WHO to National Drug Regulatory Authorities in countries to verify the accuracy of registration data for their country. 3.3 Quality Assurance The DRS database only contains data pertinent to the registration status of pharmaceutical products which have either been approved through WHO prequalification or Stringent Regulatory Authority (SRA) approved. 3.4 Procedures The data is processed in three sequential steps which involve coding, validation by algorithms to detect different types of duplicates and determination of the registration status to be displayed in the database. Registration expiry date is treated as confidential information. 3.5 Caveats When interpreting the DRS data, the following caveats need to be borne in mind: Pharmaceutical product registration is a highly dynamic area and data can therefore never be 100% accurate or complete at any given point of time; The data is provided by manufacturers on a voluntary basis and WHO makes no representations or warranties, either expressed or implied, as to its accuracy, completeness or fitness for a particular purpose; WHO accepts no responsibility or liability with regard to the reliance on, or use of, such data and information. 4
9 4. PRODUCT CATEGORIES 4.1 Antiretroviral drugs (ARVs) The DRS provides pharmaceutical product registration status in respect of 40 adult ARV formulations and 35 paediatric formulations. 4.2 TB medicines By early 2013, the DRS will include the pharmaceutical product registration status of TB medicines for both 1st and 2nd line adult formulations, together with paediatric 1st line products. 4.3 Artemisinin-based combination therapies (ACTs) By mid-2013, the DRS will include the pharmaceutical product registration status of ACTs for both 1st and 2nd line adult formulations, together with paediatric 1st line products. 5
10 5. REPORTS 5.1 Types of reports For each record entered in the DRS, data is provided as to the INN, brand name, strength, dosage form, country, manufacturer, registration status and applicable quality standard. The DRS reports have been fully automated and are simple to generate according to the information required by the user. 5.2 Accessing reports Step 1: Connect to the DRS - 6
11 Step 2: Take note of the 7 boxes which appear initially upon opening the link as per the screen shot below: Therapeutic category INN Strength Dosage Form Country you can select multiple countries by pressing the CONTROL key simultaneously with selecting the countries you wish to generate a report on Manufacturer here you have the option to either choose one manufacturer for whom you wish to generate a report. Alternatively, a report will be generated for all manufacturers if you do not select a specific manufacturer Status here you have the option to choose 1 of 4 options: expired, expiry date not provided, registered, under registration renewal 7
12 8 Quality standards here there are 2 options: WHO prequalification and SRA approved. You can select either one or both options as per the screen shot below.
13 Step 3: In addition to the regular search options, there is a box titled Display Columns see screen shot below. 9
14 Here there are 17 options (as per the screen shot below) that you can select for display in your report. If you do not select any of these options, the only information that will be shown in your report is the INN, strength and status. It is therefore important to select the reporting parameters. Brand name Manufacturer Country Country of manufacture Dosage form Dosage form detailed GFQA standard INN Manufacturer Manufacturing site Pack material Pack size Registration number SRA Status Strength WHO prequalification 10
15 Step 4: When you have selected all of your search options, click the Search tab. 11
16 12 A report will be automatically generated. If you want to start a new search, you must click the Rest Filters button see screen shot below. If you do not clear your previous searches, your new search will include the previous search criteria and your output will be incorrect
17 Step 5: If you want to export the report to Excel click on the floppy disc button (marked red in screen shot below) and then select from the pop up box the appropriate format you want. Click OK. 13
18 14 Step 6: For an advanced search, click on the top right hand side of the screen and key in your search criteria.
19 6. FREQUENTLY ASKED QUESTIONS 6.1 How often is the DSR data updated? The DRS is updated immediately when new registration data becomes available to AMDS. 6.2 What is the added value of the DRS? The DRS is a single source comprehensive mechanism whereby interested parties are able to access the global registration status of pharmaceutical products which are procured in low/ lower middle/upper middle income countries. Without the DRS, this information would not be available in the public domain. 6.3 Does the DRSD include pharmaceutical products used in the private sector market? The DRS focuses on pharmaceutical products which are required in the public sector. These products may equally be used in the private sector. 6.4 Can the DRS be expanded to include all essential medicines? In the future and subject to funding, the DRS can potentially be expanded to include the pharmaceutical product registration status of all essential medicines. However, this is not part of the existing scope of the project. Parties interested to see the project scope extended will need to convey this demand to AMDS. 6.5 Why is the pharmaceutical product registration period not specified in the DRS? This is considered to be commercial and proprietary information. 15
20 7. COMMUNICATION/VISIBILITY 7.1 Quarterly report WHO sends a quarterly report to all partners who are interested in being kept informed about DRS developments. If you would like to receive this report, please send an to amds@who.int. 7.2 Feedback We welcome your feedback with respect to utilization of the DRS, including potential enhancements that you would like to see and any problems that you would like to have rectified. Please send your feedback to amds@who.int. 16
21
22 For more information, contact: World Health Organization Department of HIV/AIDS 20, avenue Appia 1211 Geneva 27 Switzerland ISBN hiv-aids@who.int
PROPOSAL FOR UPDATING THE DEFINITION OF STRINGENT REGULATORY AUTHORITY
August 2017 Draft for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 PROPOSAL FOR UPDATING THE DEFINITION OF World Health Organization
More informationGUIDELINES ON SUBMISSION OF DOCUMENTATION FOR PREQUALIFICATION OF FINISHED PHARMACEUTICAL PRODUCTS APPROVED BY STRINGENT REGULATORY AUTHORITIES
8 July 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 GUIDELINES ON SUBMISSION OF DOCUMENTATION FOR PREQUALIFICATION OF FINISHED
More informationSHIPPERS PROGRAMME Introduction Infectious Substances Shipping Training
Infectious Substances Shipping Training Acknowledgements Slide 2 of 18 The extracts from the Recommendations on the Transport of Dangerous Goods, Model Regulations, 18 th revised edition, New York and
More informationIntroduction to the Technical Supplements
Introduction to the Technical Supplements WHO Technical Report Series, No. 961, 2011 Annex 9: Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products May
More informationIntroduction to the Technical Supplements
QAS/14.598 Main document Introduction to the Technical Supplements WHO Technical Report Series, No. 961, 2011 Annex 9: Model guidance for the storage and transport of time and temperature sensitive pharmaceutical
More informationBURULI ULCER. A guide for field health workers
BURULI ULCER A guide for field health workers Recognize Act now! WHO Library Cataloguing-in-Publication Data Buruli ulcer: recognize act now. 1.Mycobacterium infections,atypical - prevention and control.
More informationGuide for Documenting and Sharing Best Practices. in Health Programmes
Guide for Documenting and Sharing Best Practices in Health Programmes Guide for Documenting and Sharing Best Practices in Health Programmes WORLD HEALTH ORGANIZATION Regional Office for Africa Brazzaville
More informationA review of databases, resources, and online search tools that allow for monitoring health R&D activities
A review of databases, resources, and online search tools that allow for monitoring health R&D activities Explanation of methods and description of main results Accompanying the Excel file Review of data
More informationGENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES
July 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES REVISED
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.1 April 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.2 August 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
More informationPROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT
August 2010 RESTRICTED PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT Please address any comments on this draft guideline
More informationResults of WHO survey on demand for testing in WHO Scheme to Evaluate Household Water Treatment Technologies
WHO/FWC/WSH/14.05 Results of WHO survey on demand for testing in WHO Scheme to Evaluate Household Water Treatment Technologies February 2014 Geneva Switzerland World Health Organization 2014 All rights
More informationDACLATASVIR TABLETS (DACLATASVIRI COMPRESSI) Proposal for The International Pharmacopoeia. (May 2018)
May 2018 Draft for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 DACLATASVIR TABLETS (DACLATASVIRI COMPRESSI) Proposal for The International
More informationBiological Qualifier An INN Proposal. Programme on International Nonproprietary Names (INN)
INN Working Doc. 14.342 Rev. Final October 2015 Distr.: UNRESTRICTED ENGLISH ONLY Biological Qualifier An INN Proposal Programme on International Nonproprietary Names (INN) Technologies Standards and Norms
More informationWorking document QAS/ June 2011 RESTRICTED DRAFT FOR COMMENT
June 2011 RESTRICTED DRAFT PROPOSAL FOR Revision of General method in the 4th Edition of The International Pharmacopoeia 3.3 MICROBIAL PURITY OF PHARMACEUTICAL PREPARATIONS (June 2011) DRAFT FOR COMMENT
More informationPentamidine isetionate Pentamidine isetionate for injection
July 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 Pentamidine isetionate Pentamidine isetionate
More informationABRIDGED PREQUALIFICATION ASSESSMENT. Prequalification of In Vitro Diagnostics
P r e q u a l i f i c a t i o n T e a m - D i a g n o s t i c s ABRIDGED PREQUALIFICATION ASSESSMENT Prequalification of In Vitro Diagnostics PQDx_173 v3 12 September 2017 (This document version supersedes
More informationSupporting countries for HRH development: from dialogue to action
Original: English Supporting countries for HRH development: from dialogue to action Methodological note Geneva 2004 World Health Organization The World Bank Supporting countries for HRH development:from
More informationDRAFT NOTES ON THE CONDUCT OF SOLUBILITY STUDIES
August 2017 Draft working document for comment 1 2 3 4 5 6 DRAFT NOTES ON THE CONDUCT OF SOLUBILITY STUDIES (August 2017) DRAFT FOR COMMENT Should you have any comments on the attached text, please send
More informationInternational Traffic Safety
International Traffic Safety Data Systems Improvement Appendix Case Study Data System Foundations WHO Library Cataloguing-in-Publication Data International traffic safety: data systems improvement. 3 v.
More informationWorking document QAS/11.415/Rev. 1 August 2011 RESTRICTED DRAFT FOR COMMENT
/Rev. 1 August 2011 RESTRICTED DRAFT PROPOSAL FOR Revision of General method in the 4th Edition of The International Pharmacopoeia 3.3 MICROBIAL Quality PURITY OF PHARMACEUTICAL PREPARATIONS (August 2011)
More informationUser s Manual. Tool for Calculation of Drug Quantities and ARV Unit Costs. Round 10
Tool for Calculation of Drug Quantities and ARV Unit Costs User s Manual For Use in Completion of The Pharmaceutical and Health Products List To HIV/AIDS Funding Applications to The Global Fund to Fight
More informationWHO Prequalification of Medicines Programme (WHO-PQP): Ensuring quality medicines
WHO Prequalification of Medicines Programme (WHO-PQP): Ensuring quality medicines Dr Lembit Rägo Essential Medicines and Health Products World Health Organization Geneva Switzerland ragol@who.int 1 Context
More informationSession 1: Prequalification and Procurement
Session 1: Prequalification and Procurement Session Objectives Discuss aims of the World Health Organization (WHO) Prequalification Programme Explain the role of the United Nations Population Fund (UNFPA)
More informationINTERNATIONAL PHARMACOPOEIA MONOGRAPH ON ARTEMETHER AND LUMEFANTRINE CAPSULES REVISED DRAFT FOR DISCUSSION
October 2007 RESTRICTED ` INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON ARTEMETHER AND LUMEFANTRINE CAPSULES REVISED DRAFT FOR DISCUSSION World Health Organization 2007 All rights reserved. This draft is intended
More informationCONCEPT PAPER FOR COMMENT
April 2017 Draft document for comment 1 2 3 4 5 6 7 8 CONCEPT PAPER FOR COMMENT TRANSITION FROM MICROBIOLOGICAL TO PHYSICOCHEMICAL ASSAYS IN MONOGRAPHS ON CAPREOMYCIN ACTIVE PHARMACEUTICAL INGREDIENTS
More informationExpert consultation on the development of a plan of action for food safety in the Eastern Mediterranean Region
Summary report on the Expert consultation on the development of a plan of action for food safety in the Eastern Mediterranean Region 2017 2022 WHO-EM/CEH/158/E Amman, Jordan 2 3 August 2016 Summary report
More informationGUIDELINES FOR REGISTRATION OF IMPORTERS AND FOR THE IMPORTATION OF MEDICINES AND RELATED PRODUCTS
MEDICINES CONTROL AGENCY 54 Kairaba Avenue, Pipeline, The Gambia. Tel.no. +220 4380632 GUIDELINES FOR REGISTRATION OF IMPORTERS AND FOR THE IMPORTATION OF MEDICINES AND RELATED PRODUCTS Document no: MCA/IMPG/2017/1
More informationWHO GLOBAL BENCHMARKING TOOL (GBT) FOR EVALUATION OF NATIONAL REGULATORY SYSTEM OF MEDICAL PRODUCTS
0 WHO GLOBAL BENCHMARKING TOOL (GBT) FOR EVALUATION OF NATIONAL REGULATORY SYSTEM OF MEDICAL PRODUCTS FACT SHEETS FOR REGISTRATION AND MARKETING AUTHORIZATION (DRAFT REVISION VI VERSION ) (DECEMBER ) DRAFT
More informationWHY UNITAID MATTERS FOR PEOPLE LIVING WITH HIV/AIDS, TB AND MALARIA MARKET IMPACT
WHY UNITAID MATTERS FOR PEOPLE LIVING WITH HIV/AIDS, TB AND MALARIA MARKET IMPACT by the Civil Society Delegations to UNITAID PROBLEM SOLUTION MARKET JOURNEY GOAL 1 No appropriate product Product adapted
More informationMeeting of the Eastern Mediterranean Research Ethics Review Committee
Summary report on the Meeting of the Eastern Mediterranean Research Ethics Review Committee WHO-EM/RPC/038/E Cairo, Egypt 6 7 September 2015 WHO-EM/RPC/038/E Summary report on the Meeting of the Eastern
More informationA Review of the PA-824 Patent Landscape
2014 A Review of the PA-824 Patent Landscape A scoping report JANUARY 2014 A Review of the PA-824 Patent Landscape UNITAID Secretariat World Health Organization Avenue Appia 20 CH-1211 Geneva 27 Switzerland
More informationBiological Qualifier An INN Proposal. Programme on International Nonproprietary Names (INN)
INN Working Doc. 14.342 Revised draft June 2015 Distr.: RESTRICTED ENGLISH ONLY Biological Qualifier An INN Proposal Programme on International Nonproprietary Names (INN) Technologies Standards and Norms
More informationREPORT OF THE MARKET DYNAMICS AND COMMODITIES AD HOC COMMITTEE
Twentieth Board Meeting Addis Ababa, Ethiopia 9 11 November 2009 Information REPORT OF THE MARKET DYNAMICS AND COMMODITIES AD HOC COMMITTEE OUTLINE: 1. This report summarizes the deliberations of the Market
More informationDraft proposal for The International Pharmacopoeia
ctober 2015 Draft document for comment MISPRSTL Draft proposal for The International Pharmacopoeia (January 2015) DRAFT FR CMMENT Should you have any comments on this draft please send these to Dr erbert
More informationReport on meetings of expert committees and study groups 1
EXECUTIVE BOARD EB137/9 137th session 27 March 2015 Provisional agenda item 10 Report on meetings of expert committees and study groups 1 Report by the Secretariat SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS
More informationRevised Global Fund Quality Assurance Policy for Pharmaceutical Products and Price &Quality Reporting
Revised Global Fund Quality Assurance Policy for Pharmaceutical Products and Price &Quality Reporting AIDS Medicines and Diagnostics Services (AMDS) Partners and Stakeholders Meeting, Board Decision on
More informationConsultation on health workforce development in the Eastern Mediterranean Region
Summary report on the Consultation on health workforce development in the Eastern Mediterranean Region WHO-EM/HRH/633/E Cairo, Egypt 2 4 December 2014 Summary report on the Consultation on health workforce
More informationTHE INTERNATIONAL PHARMACOPOEIA
June 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 THE INTERNATIONAL PHARMACOPOEIA RADIOPHARMACEUTICALS:
More informationJANUARY I. Purpose of this invitation for EoI. II. Background
First Global Fund and Global Drug facility Invitation to manufacturers of first, second and third-line anti-tuberculosis medicines to submit an Expression of Interest (EoI) for product evaluation by Expert
More informationWater and Health UNITED NATIONS
UNITED NATIONS The Ad Hoc Project Facilitation Mechanism (AHPFM): mainstreaming international support for country action within the Protocol on Water and Health In the 21 st century, water-related diseases
More informationMDR-TB PROCUREMENT REQUEST FORM AND TECHNICAL AGREEMENT (MPTA)
MDRTB PROCUREMENT REQUEST FORM AND TECHNICAL AGREEMENT (MPTA) Agreed between Name of Institution Address (hereinafter Client ) and Global Drug Facility, Stop TB Partnership Secretariat, c/o World Health
More informationYour Health. Your Safety. Our Commitment. Workplace Violence Risk Assessment Tool. User Guide for Acute Care and Long Term Care
Your Health. Your Safety. Our Commitment. Workplace Violence Risk Assessment Tool User Guide for Acute Care and Long Term Care Workplace Violence Risk Assessment Tool - User Guide for Acute Care and Long
More informationSession 13: Prequalification Within the Context of Global Fund Procurements
Session 13: Prequalification Within the Context of Global Fund Procurements Established in 2002 Global Fund Attracts and disburses additional resources to prevent and treat AIDS, tuberculosis (TB), and
More informationFairsail Collaboration Portal: Guide for Users
Fairsail Collaboration Portal: Guide for Users Version 11 FS-HCM-CP-UG-201504--R011.00 Fairsail 2015. All rights reserved. This document contains information proprietary to Fairsail and may not be reproduced,
More informationPharmaceutical product technical requirements and the Interagency pharmaceutical product questionnaire
Pharmaceutical product technical requirements and the Interagency pharmaceutical product questionnaire Atieno Ojoo Technical specialist, Pharmaceuticals UNICEF Supply Division 20 th October 2008, UNICEF
More informationUNITAID. Increasing access to quality medicines and diagnostics for HIV/AIDS,TB and Malaria
UNITAID Increasing access to quality medicines and diagnostics for HIV/AIDS,TB and Malaria 4 th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines and Vaccines 03 February 2009
More informationREVISED DRAFT FOR COMMENT
March 2014 Document for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 THE INTERNATIONAL PHARMACOPOEIA RADIOPHARMACEUTICALS: SPECIFIC MONOGRAPH
More informationGLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE
GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE Finished Pharmaceutical Product Questionnaire This questionnaire is used to collect information from vendors with regards to finished pharmaceutical products
More informationCost savings of switching private sector consumption from originator brand medicines to generic equivalents
Cost savings of switching private sector consumption from originator brand medicines to generic equivalents Alexandra Cameron and Richard Laing World Health Report (2010) Background Paper, 35 HEALTH SYSTEMS
More informationGUIDANCE ON VARIATIONS TO A PREQUALIFIED DOSSIER
RESTRICTED GUIDANCE ON VARIATIONS TO A PREQUALIFIED DOSSIER Since being presented to the Fortieth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2005 this
More informationGUIDELINES FOR REGISTRATION OF MEDICINES IN THE GAMBIA
MEDICINES CONTROL AGENCY 54 Kairaba Avenue, Pipeline, The Gambia. Tel.no. +220 4380632 GUIDELINES FOR REGISTRATION OF MEDICINES IN THE GAMBIA Document no: MCA/MRG/2017/1 Date of issue: 25 th July 2017
More informationWorld Health Organization. Standard-setting Activities Impact on Global Health
Standard-setting Activities Impact on Global Health Dr Vladimir K. Lepakhin Assistant Director-General Health Technology and Pharmaceuticals, Geneva 26-27 February 2004-1 1 WHO Standard-setting Activities
More informationRegional meeting on food safety
Summary report on the Regional meeting on food safety WHO-EM/CEH/155/E Amman, Jordan 5 7 April 2015 Summary report on the Regional meeting on food safety Amman, Jordan 5 7 April 2015 World Health Organization
More informationWHO Prequalification of Medicines Programme application fees
WHO Prequalification of Medicines Programme application fees This document explains the fees that apply to applications to prequalify medicines or active pharmaceutical ingredients and applications for
More informationQuality assurance for essential medicines and health products. IPC meeting: December 2012
Quality assurance for essential and health products IPC meeting: December 2012 Pharmaceutical Products QA Policy (June 2009) December 2010: requirements to purchase ACTs FDC in priority Condoms Procurement
More informationHIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005
HIKMA PHARMACEUTICALS PLC Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 Important notice This document and its contents are confidential and may not be redistributed or
More informationEBOLA VIRUS DISEASE FLIP BOOK TRAINING GOWHO GO PRE-DEPLOYMENT TRAINING
EBOLA VIRUS DISEASE FLIP BOOK TRAINING GOWHO GO PRE-DEPLOYMENT TRAINING WHO Library Cataloguing-in-Publication Data: Go training: package for Ebola pre-deployment. Contents: Participant handbook Ebola
More informationSAP GRC Global Trade Services 7.2 Preferred Practice US Automated Export Systems (AES)
SAP GRC Global Trade Services 7.2 Preferred Practice US Automated Export Systems (AES) SAP GRC Updated September 2010 2 1. Table of Contents 1. Introduction...3 2. Prerequisites...4 3. Scenario Description...5
More informationAriba Network Invoice Guide
Ariba Network Invoice Guide Content 1. Introduction 2. Invoice Practices 3. Before you Begin Invoicing I. Viewing Customer Invoice Rules II. Electronic Invoice Routing and notifications III. Account Configuration
More informationRegional training workshop on sanitation/ wastewater safety planning
Summary report on the Regional training workshop on sanitation/ wastewater safety planning WHO-EM/CEH/162/E Amman, Jordan 24 27 July 2017 WHO-EM/CEH/162/E Summary report on the Regional training workshop
More informationGuidelines for price discounts of single-source pharmaceuticals
WHO/EDM/PAR/2003.3 Guidelines for price discounts of single-source pharmaceuticals World Health Organization Joint United Nations Programme on HIV/AIDS United Nations Children's Fund United Nations Population
More informationTABLE OF CONTENTS P a g e
Unitaid TABLE OF CONTENTS 1. 2. 3. 4. 5. 6. 7. Background... 3 Purpose... 3 Scope... 3 Principles... 4 Procurement Approaches, Responsibilities, Standards, Norms and Obligations... 5 Compliance with Applicable
More informationManufacture of Sulfadoxine-Pyrimethamine (Drug Product and Drug Substance), for Intermittent Preventive Treatment of Malaria in Pregnancy (IPTp)
REQUEST FOR INFORMATION (RFI) Manufacture of Sulfadoxine-Pyrimethamine (Drug Product and Drug Substance), for Intermittent Preventive Treatment of Malaria in Pregnancy (IPTp) RFI Reference: MMV-2017-IPTp-SP
More informationSession 5: Increase in Use of the WHO Prequalification Programme
Session 5: Increase in Use of the WHO Prequalification Programme Perceived Need for Prequalification In an ideal world: Regulated pharmacies and service providers would supply medicines to clients Regulatory
More informationAriba Network Ship Notice Guide
Ariba Network Ship Notice Guide Content Introduction Network Requirements Ship Notices Ariba Network Support 2016 SAP SE or an SAP affiliate company. All rights reserved. Public 2 Introduction Introduction
More informationRequirements for Yellow Fever Vaccine (Requirements for Biological Substances No. 3) Proposed Amendment
ENGLISH ONLY FINAL EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 13 to 17 October 2008 Requirements for Yellow Fever Vaccine (Requirements for Biological Substances No. 3) Proposed Amendment NOTE:
More informationI. Purpose. II. Definitions. Last Approval Date
Investigational Drugs and Biologics Page 1 of 13 I. Purpose The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics
More informationElectronic Invoicing
Electronic Invoicing InvoiceWorks Supplier User Guide (Participating Supplier) ipayables Inc. 2007 ipayables Technical Support Supplier User Guide Check the Help Menu item for assistance with that screen
More informationOn Approval of the Rules on Importation and Exportation of Medicines, Products of Medical Purposes and Medical Equipment
On Approval of the Rules on Importation and Exportation of Medicines, Products of Medical Purposes and Medical Equipment Resolution of the Government of the Republic of Kazakhstan No. 711 of 31 May 2012
More informationSAP BUSINESSOBJECTS PLANNING AND CONSOLIDATION 10.0, VERSION FOR SAP NETWEAVER STARTER KIT FOR IFRS SP1. Simplified Configuration Description
SAP BUSINESSOBJECTS PLANNING AND CONSOLIDATION 10.0, VERSION FOR SAP NETWEAVER STARTER KIT FOR IFRS SP1 Simplified Configuration Description 1 Copyright 2012 SAP AG. All rights reserved. SAP, R/3, SAP
More informationGUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET
GUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda
More informationThis document has been provided by the International Center for Not-for-Profit Law (ICNL).
This document has been provided by the International Center for Not-for-Profit Law (ICNL). ICNL is the leading source for information on the legal environment for civil society and public participation.
More informationInterQual View Quick Reference. Change Healthcare LLC Product Support
InterQual View 2018 Quick Reference Change Healthcare LLC www.changehealthcare.com Product Support 800.274.8374 PROPRIETARY NOTICE General Terms: Change Healthcare LLC and/or one of its subsidiaries (
More informationChallenges in Archiving SharePoint documents to a file server / file share
Challenges in Archiving SharePoint documents to a file server / file share White Paper Published by: Vyapin Software Systems http://www.vyapin.com Abstract SharePoint is fast becoming the all-in-one repository
More informationInterQual View Quick Reference. Change Healthcare Operations LLC Product Support
InterQual View 2017 Quick Reference Change Healthcare Operations LLC www.changehealthcare.com Product Support 800.274.8374 General Terms: Change Healthcare Operations, LLC and/or one of its subsidiaries
More informationOVERVIEW OF THE PREQUALIFICATION OF MALE CIRCUMCISION DEVICES ASSESSMENT PROCESS
D i a g n o s t i c s a n d L a b o r a t o r y T e c h n o l o g y OVERVIEW OF THE PREQUALIFICATION OF MALE CIRCUMCISION DEVICES ASSESSMENT PROCESS Prequalification of Male Circumcision Devices PQMC_007
More informationCurrent version 13 October 2016
Implementation Working Group ICH Q11 Guideline: DEVELOPMENT AND MANUFACTURE OF DRUG SUBSTANCES (CHEMICAL ENTITIES AND BIOTECHNOLOGICAL/BIOLOGICAL ENTITIES) and Current version 13 October 2016 In order
More informationInnovative regulatory thinking to advance pediatric product development:
Innovative regulatory thinking to advance pediatric product development: Prequalification's efforts to address immediate need as guidance to aid long term development progresses Dr. John Gordon WHO Consultant
More informationInternationally harmonised requirements for batch certification
1 June 2011 EMA/INS/MRA/387218/2011 Rev 5 Compliance and Inspection Internationally harmonised requirements for batch certification in the context of Mutual Recognition Agreements, Agreements on Conformity
More informationDemo Script. Procure-to-Pay - Stock Classification: Internal and for Partners. SAP Business ByDesign Reference Systems.
Demo Script Procure-to-Pay - Stock Classification: Internal and for Partners SAP Business ByDesign Reference Systems Table of Content 1 Demo Script Overview... 3 1.1 Demo Overview... 3 1.2 Intended Audience...
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public health and Risk assessment Pharmaceuticals Brussels, 01 June 2010 SANCO/C/8/SF/dn D(2010) 326199 THE RULES GOVERNING MEDICINAL PRODUCTS
More informationAPI Assessment Activities. Antony Fake, PhD
API Assessment Activities Antony Fake, PhD 2 Overview APIMF Procedure API PQ Procedure What is new? 3 Abbreviations API Active Pharmaceutical Ingredient FPP Finished Pharmaceutical Product API PQ API Prequalification
More informationZebra s Repair Order Portal for Partners COURSE CODE: RPE01
Zebra s Repair Order Portal for Partners COURSE CODE: RPE01 April 2017 Introduction Welcome to the Zebra s Repair Order Portal for Partners course. This course explains how to navigate the Repair Order
More informationRETAIL COMPLIANCE PROGRAM 2016
RETAIL COMPLIANCE PROGRAM 2016 To get started now, visit www.globalrsinc.com/hallmark Global Registration Services, Inc. 1674 S. Research Loop, Suite 436 www.globalrsinc.com Tucson, AZ 85710 (00-1) 312-405-9467
More informationInvoice Upload Guide THE BEST RUN. ADMINISTRATION GUIDE PUBLIC Release a (incubation release, not globally available)
ADMINISTRATION GUIDE PUBLIC Release 1.0-2018.10a (incubation release, not globally available) 2018-10-24 2018 SAP SE or an SAP affiliate company. All rights reserved. THE BEST RUN Content 1 Introduction....3
More informationSAP Education: Reporting Access User Guide
www.sap.com SAP Education: Reporting Access User Guide The Best-Run Businesses Run SAP Accessing Reports Login to the Learning Hub with credentials you have been provded with: To access the reports click
More informationHOW TO CONFIGURE SINGLE SIGN-ON (SSO) FOR SAP CLOUD FOR CUSTOMER USING SAP CLOUD IDENTITY SERVICE
HOW TO CONFIGURE SINGLE SIGN-ON (SSO) FOR SAP CLOUD FOR CUSTOMER USING SAP CLOUD IDENTITY SERVICE HOW TO GUIDE TABLE OF CONTENTS Overview... 3 Chapter 1: Configure SAP Cloud Identity service... 5 Creating
More informationGDF: Global mechanism to facilitate access to affordable quality assured TB medicines and diagnostics
The Global Drug Facility (GDF) GDF: Global mechanism to facilitate access to affordable quality assured TB medicines and diagnostics Dr Kaspars Lunte Global Sourcing Officer, GDF 19 September 2017 Copenhagen
More informationAPI Assessment Activities
API Assessment Activities Antony Fake PhD WHO Medicines Prequalification Programme 1 3.2.S.3.2 Impurities, Malaysia, 29 September 2011 2 Overview APIMF Procedure API PQ Procedure What is new? 3 Abbreviations
More informationGDF, the Global mechanism to facilitate access to affordable quality assured TB medicines and diagnostics, including new tools
The Global Drug Facility (GDF) GDF, the Global mechanism to facilitate access to affordable quality assured TB medicines and diagnostics, including new tools Magali Babaley Strategic Procurement and Business
More informationTERMS OF REFERENCE. The form and function of the Stop TB Partnership Working Group on New Drugs, Its Core Group (CG), Subgroups and Secretariat
TERMS OF REFERENCE The form and function of the Stop TB Partnership Working Group on New Drugs, Its Core Group (CG), Subgroups and Secretariat 1 Rationale for the Stop TB Working Group on New Drugs (hereinafter
More informationFairsail. Administrator. Supporting the Salary Planning Process. Version 1.0 FS-HCM-SP-AG R001.00
Fairsail Administrator Supporting the Salary Planning Process Version 1.0 FS-HCM-SP-AG-201309--R001.00 Fairsail 2013. All rights reserved. This document contains information proprietary to Fairsail and
More informationWHO Pre-Qualification Programme: Facilitating Regional Approval and Patient Access to Treatments
WHO Pre-Qualification Programme: Facilitating Regional Approval and Patient Access to Treatments A Decade of R&D for Neglected Diseases in Africa Nairobi, Kenya, 4-5 June 2013 Hiiti B. Sillo Director General
More informationProcurement and Quality Assurance Updates
Procurement and Quality Assurance Updates Joint meeting UNICEF, WHO, UNFPA with manufacturers and suppliers 19 September 2017 Sophie Logez, Health Product Management Hub Outline Overview of the Global
More informationBiological Qualifier Frequently Asked Questions
INN Working Doc. 15.382 Final October 2015 Distr.: UNRESTRICTED ENGLISH ONLY Biological Qualifier Frequently Asked Questions Programme on International Nonproprietary Names (INN) Technologies Standards
More informationUse Variables for Currency Conversion
How to Use Variables for Currency Conversion BUSINESS INFORMATION WAREHOUSE ASAP How to Paper Applicable Releases: SAP BW 3.0B, SP 16/BW 3.1Content, SP 10 December 2003 SAP (SAP America, Inc. and SAP AG)
More informationHealthy Villages. A guide for communities and community health workers
Healthy Villages A guide for communities and community health workers Guy Howard Water, Engineering and Development Centre Loughborough University, Loughborough, England with Claus Bogh Bilharziasis Laboratory,
More information